The current treatments and drugs of myocardial infarction (MI) remain insufficient. In recent years, natural products have garnered significant attention for their potential in treating cardiovascular diseases due to their availability and lower toxicity. Saponins, in particular, showed promising effects for cardiac protection.
View Article and Find Full Text PDFGlycosylated RNAs (glycoRNAs) have recently emerged as a new class of molecules of substantial interest owing to their potential roles in cellular processes and diseases. However, studying glycoRNAs is challenging owing to the lack of effective research tools including, but not limited to, imaging techniques to study the spatial distribution of glycoRNAs. Recently, we reported the development of a glycoRNA imaging technique, called sialic acid aptamer and RNA in situ hybridization-mediated proximity ligation assay (ARPLA), to visualize sialic acid-containing glycoRNAs with high sensitivity and specificity.
View Article and Find Full Text PDFSoft actuators for intelligent robots require further elaboration to improve their biomedical applicability, which has led to the development of a series of flexible stimulus-responsive materials. However, fabricating degradable soft actuators that exhibit synergistic color and shape changes in response to environmental stimuli remains challenging. Here, we developed a soft actuating gel based on carbon dots (CDs) that are chemically cross-linked with sodium alginate.
View Article and Find Full Text PDFIn the domain of online reinforcement learning, strategies that leverage inherent rewards for exploration tend to achieve commendable outcomes within contexts characterized by deceptive or sparse rewards. Counting through the visitation of states is an efficient count-based exploration method to get the proper intrinsic reward. However, only the novelty of the states encountered by the agent is considered in this exploration method, resulting in the over-exploration of a certain state-action pair and falling into a locally optimal solution.
View Article and Find Full Text PDFPurpose: Neoadjuvant immune checkpoint blockade with nivolumab plus ipilimumab improves overall survival (OS) in non-small cell lung cancer (NSCLC); however, randomized data for resectable lung cancer are limited. We report results from the exploratory concurrently randomized nivolumab plus ipilimumab and chemotherapy arms of the international phase III CheckMate 816 trial.
Methods: Adults with stage IB-IIIA (American Joint Committee on Cancer seventh edition) resectable NSCLC received three cycles of nivolumab once every 2 weeks plus one cycle of ipilimumab or three cycles of chemotherapy (on day 1 or days 1 and 8 of each 3-week cycle) followed by surgery.